Literature DB >> 29377573

Intrabronchial display of hilar-mediastinal lymph nodes by virtual bronchoscopic navigation system.

Xiaodong Wu1, Lingzhi Shi2, Yang Xia3, Ko-Pen Wang4, Qiang Li1.   

Abstract

The description of precise intrabronchial positions for the sampling of mediastinal-hilar lymph nodes is critical to successfully perform conventional transbronchial needle aspiration. Previously published maps of mediastinal-hilar lymph nodes were primarily drawn based on experts' experience. We generated a virtual map of the most frequently sampled intrathoracic lymph nodes from an intrabronchial perspective using a virtual bronchoscopic navigation system, to assist with training in conventional transbronchial needle aspiration.
© 2018 The Authors. Thoracic Cancer published by China Lung Oncology Group and John Wiley & Sons Australia, Ltd.

Entities:  

Keywords:  zzm321990Bronchoscopy; lymph nodes; transbronchial needle aspiration; virtual bronchoscopic navigation

Mesh:

Year:  2018        PMID: 29377573      PMCID: PMC5832480          DOI: 10.1111/1759-7714.12555

Source DB:  PubMed          Journal:  Thorac Cancer        ISSN: 1759-7706            Impact factor:   3.500


Introduction

Transbronchial needle aspiration (TBNA) is now a well‐established bronchoscopic technique for sampling mediastinal‐hilar adenopathy and masses. This technique was first performed by Dr. Ko‐Pen Wang in 1978 via the flexible bronchoscope, and revolutionized diagnosis of mediastinal and hilar adenopathy.1 However, conventional TBNA (cTBNA) is a relatively blind technique, and thus remains underutilized because of concerns over safety and unpredictable sensitivity. Emerging endobronchial ultrasound‐TBNA (EBUS‐TBNA) has proven superior to cTBNA in terms of the diagnostic yield and safety because of direct visualization of the needle while crossing the tracheobronchial wall and sampling the lesions.2, 3, 4, 5 However, the requirement of high‐cost equipment and general anesthesia limits the widespread application of EBUS‐TBNA in less developed regions.6, 7 In contrast, cTBNA, with the use of regular equipment, lower cost, and ease of performance and training has the potential for wide application. An in‐depth knowledge of lymph node (LN) positions from an intrabronchial view is a vital factor contributing to eventual diagnostic yield. In 1994, Wang published a TBNA map of mediastinal‐hilar LNs from an intrabronchial perspective based on his experience with conventional TBNA.8 However, Wang's nodal map failed to present the precise intrabronchial areas that exactly display intrathoracic LNs. More concise and intuitive characterization of hilar‐mediastinal LNs from an intrabronchial view would assist the cTBNA training process and promote its use. An alternative approach to generate an intrabronchial view of hilar‐mediastinal LNs is the use of a virtual bronchoscopic navigation (VBN) system. Virtual bronchoscopy is a method for displaying a three‐dimensional (3D) view of the airway lumens by reconstructing the continuous volume data of helical computed tomography (CT), resembling the real‐life bronchoscopic view.9 It was originally intended to guide peripheral lung lesion sampling,10, 11 airway stenosis evaluation,12 postoperative bronchial complications, and tracheal/bronchial injury.13, 14 We herein generate a virtual intrabronchial map of hilar‐mediastinal LNs using a VBN system to present an intuitive impression of the localization of biopsy sites for bronchoscopists.

Methods

Using the SPiN Thoracic Navigation System (Veran Medical Technologies, St Louis, MO, USA), 3D spherical markers are placed in the location of intrathoracic LNs on a CT image. Subsequently, 3D images of the airway tree are automatically generated and the target LN is displayed in color by virtual bronchoscopic animation.

Results

We sequentially marked the anatomic location of intrathoracic LNs as the target, and then generated a virtual display from an intrabronchial perspective. To better illustrate intrathoracic LNs, we used both Wang's map and the International Association for the Study of Lung Cancer (IASLC) nodal map. The IASLC nodal map has been applied to describe tumor node metastasis (TNM) staging of lung cancer; the close correlation between Wang's map and the IASLC map has been widely recognized (Table 1).
Table 1

Correlation between Wang's map and the IASLC map

Wang's mapIASLC map
Station 1, 3, 54R
Station 4, 64L
Station 2,8,107
Station 7, 911R
Station 1111L

IASLC, International Association for the Study of Lung Cancer.

Correlation between Wang's map and the IASLC map IASLC, International Association for the Study of Lung Cancer. Figure 1 shows the virtual intrabronchial display of 4R LNs in the IASLC nodal map (Fig 1a presents a 3D view of the intrathoracic LNs). According to Wang's LN map, station 1 anterior carina LNs are shadowed on the areas around the first tracheal cartilage ring and slightly toward the right (Fig 1b), while station 3 right paratracheal LNs are located around the third tracheal inter cartilaginous space above the carina at about the two o'clock position (Fig 1c). Right main bronchus (RMB) station 5 LNs are mapped above the opening of the RMB (Fig 1d).
Figure 1

Virtual intrabronchial view of region 4R in the International Association for the Study of Lung Cancer map. (a) The three‐dimensional view of intrathoracic lymph nodes. (b–d) Stations 1, 3, and 5 in Wang's lymph node map, respectively. LMB, left main bronchus; RMB, right main bronchus.

Virtual intrabronchial view of region 4R in the International Association for the Study of Lung Cancer map. (a) The three‐dimensional view of intrathoracic lymph nodes. (b–d) Stations 1, 3, and 5 in Wang's lymph node map, respectively. LMB, left main bronchus; RMB, right main bronchus. Region 4L LNs in the IASLC map are illustrated in Figure 2. Station 4 left paratracheal LNs in Wang's map are displayed in the aortic‐pulmonary artery window at approximately the nine o'clock position (Fig 2a), while station 6 left main bronchus (LMB) LNs are projected just above the opening of the LMB (Fig 2b).
Figure 2

Virtual intrabronchial view of region 4L in the International Association for the Study of Lung Cancer map. (a,b) Stations 4 and 6 in Wang's lymph node map, respectively. LMB, left main bronchus; RMB, right main bronchus.

Virtual intrabronchial view of region 4L in the International Association for the Study of Lung Cancer map. (a,b) Stations 4 and 6 in Wang's lymph node map, respectively. LMB, left main bronchus; RMB, right main bronchus. Region 7 LNs in the IASLC map correlating to the posterior carina, subcarina, and sub‐subcarinal LNs as station 2, 8, and 10 in Wang's LN map, respectively, are interpreted in Figure 3. The projection of station 2 is at the medial posterior wall of the opening of the RMB, station 8 is displayed on the carina and the medial wall of the RMB, and station 10 is shadowed at the medial posterior wall of the bronchus intermedius below the right upper bronchus.
Figure 3

Virtual intrabronchial view of region 7 in the International Association for the Study of Lung Cancer map. (a–c) Stations 2, 8, and 10 in Wang's lymph node map, respectively. LMB, left main bronchus; RMB, right main bronchus.

Virtual intrabronchial view of region 7 in the International Association for the Study of Lung Cancer map. (a–c) Stations 2, 8, and 10 in Wang's lymph node map, respectively. LMB, left main bronchus; RMB, right main bronchus. Right upper hilar LNs in Wang's station 7, as well as right lower hilar LN in Wang's station 9 correlating with region 11R in the IASLC map are located at the anterior aspect of the right upper lobe spur and at the anterior lateral aspect of the bronchus intermedius (Fig 4a,b). Wang's station 11, known as left hilar LNs and identical to region 11L in the IASLC map, is displayed at the middle aspect of the left upper lobe spur (Fig 4c).
Figure 4

Virtual intrabronchial view of regions 10R and 10L in the International Association for the Study of Lung Cancer map. (a–c) Stations 7, 9, and 11 in Wang's lymph node map, respectively.

Virtual intrabronchial view of regions 10R and 10L in the International Association for the Study of Lung Cancer map. (a–c) Stations 7, 9, and 11 in Wang's lymph node map, respectively.

Discussion

In this report, we generated an endobronchial map of intrathoracic LNs using a VBN system. This virtual map concisely illustrates the endobronchial locations of the most frequently sampled LN stations, including 4R/L, 7R/L, 10R/L, and 11R/L in the IASLC nodal map. The first advantage of this virtual map is the 3D reconstruction of the helical chest CT, reflecting actual anatomical structure and avoiding the potential bias of subjective factors compared to previous maps. Secondly, virtual bronchoscopy can be utilized as guidance for cTBNA procedures, especially to train beginners, as virtual bronchoscopy images resemble the live bronchoscopic view so well that they could facilitate the determination of the exact puncture sites for target LNs. Thirdly, VBN may show an advantage for some LN stations that have unclear intraluminal landmarks in contrast to LN stations with clear landmarks. For instance, before performing cTBNA of nodal station 2 in Wang's map, we have to undergo a thorough review of chest CT images to locate the level of opposite bronchial cartilaginous ring. However, VBN guidance would skip this step and directly navigate the operator to the puncture site. Fourthly, using a next‐generation VBN system, virtual image information of the large vessels outside the bronchus could also be superimposed on the live bronchoscopic images during cTBNA, hence averting the incidence of severe bleeding from large vessel injuries. Finally, for LNs or lesions adjacent to the secondary or tertiary bronchi that cannot be reached by EBUS‐TBNA, virtual bronchoscopy‐assisted cTBNA would be applicable to achieve cytopathological evaluation. Interestingly, this virtual map has high consistency with Wang's map.15 The efficiency of cTBNA in sampling intrathoracic LNs guided by Wang's map demonstrates the accuracy of puncture positions. The sensitivity of cTBNA for detecting and staging lung cancer is reported to be between 60% and 90%,16, 17 the accuracy of diagnosis of tuberculous lymphadenitis is 50–85%18 and 20–60% in sarcoidosis.19, 20 Our map further validated the accuracy of Wang's map for the depiction of puncture sites for cTBNA. Another map of optimal TBNA areas for intrathoracic LNs has been proposed based on pictures drawn by four experienced physicians from three centers.21 It is notable that this LN position map has good consistency with our virtual map and Wang's map, especially of stations 4L, 11R, and 11L. However, the authors described LNs using the IASLC map, which has shown limitations in guiding TBNA compared to Wang's map.22 Hence, the LMB, RMB, posterior carina, and sub‐subcarinal LNs are not mentioned in this map, which further explains the lack of agreement on station 4R. Our virtual map of intrathoracic LNs from an intrabronchial view might be helpful to train physicians for cTBNA because of its visual impression. The virtual navigation system has the advantage of real‐time guidance for cTBNA procedures, which could be further investigated in the future.

Disclosure

No authors report any conflict of interest.
  22 in total

Review 1.  Multidetector CT-generated virtual bronchoscopy: an illustrated review of the potential clinical indications.

Authors:  W De Wever; V Vandecaveye; S Lanciotti; J A Verschakelen
Journal:  Eur Respir J       Date:  2004-05       Impact factor: 16.671

2.  Understanding the economic impact of introducing a new procedure: calculating downstream revenue of endobronchial ultrasound with transbronchial needle aspiration as a model.

Authors:  Nicholas J Pastis; Suzanne Simkovich; Gerard A Silvestri
Journal:  Chest       Date:  2012-02       Impact factor: 9.410

Review 3.  Staging of bronchogenic carcinoma by bronchoscopy.

Authors:  K P Wang
Journal:  Chest       Date:  1994-08       Impact factor: 9.410

4.  Randomized trial of endobronchial ultrasound-guided transbronchial needle aspiration under general anesthesia versus moderate sedation.

Authors:  Roberto F Casal; Donald R Lazarus; Kristine Kuhl; Graciela Nogueras-González; Sarah Perusich; Linda K Green; David E Ost; Mona Sarkiss; Carlos A Jimenez; Georgie A Eapen; Rodolfo C Morice; Lorraine Cornwell; Sheila Austria; Amir Sharafkanneh; Rolando E Rumbaut; Horiana Grosu; Farrah Kheradmand
Journal:  Am J Respir Crit Care Med       Date:  2015-04-01       Impact factor: 21.405

5.  A randomized controlled trial of standard vs endobronchial ultrasonography-guided transbronchial needle aspiration in patients with suspected sarcoidosis.

Authors:  Alain Tremblay; David R Stather; Paul MacEachern; Moosa Khalil; Stephen K Field
Journal:  Chest       Date:  2009-02-02       Impact factor: 9.410

6.  Bronchoscopic needle aspiration biopsy of paratracheal tumors.

Authors:  K P Wang; P Terry; B Marsh
Journal:  Am Rev Respir Dis       Date:  1978-07

7.  Transbronchial needle aspiration: development history, current status and future perspective.

Authors:  Huizhen Yang; Yuan Zhang; Ko-Pen Wang; Yun Ma
Journal:  J Thorac Dis       Date:  2015-12       Impact factor: 2.895

8.  Virtual bronchoscopic navigation combined with endobronchial ultrasound to diagnose small peripheral pulmonary lesions: a randomised trial.

Authors:  Takashi Ishida; Fumihiro Asano; Koichi Yamazaki; Naofumi Shinagawa; Satoshi Oizumi; Hiroshi Moriya; Mitsuru Munakata; Masaharu Nishimura
Journal:  Thorax       Date:  2011-07-11       Impact factor: 9.139

9.  Utilization of the International Association for the Study of Lung Cancer and Wang's nodal map for the identification of mediastinum and hilar lymph nodes.

Authors:  Yang Xia; Yun Ma; Sixto Arias; Hans Lee; Ko-Pen Wang
Journal:  Thorac Cancer       Date:  2015-01-08       Impact factor: 3.500

10.  Diagnostic yield and safety of C-TBNA in elderly patients with lung cancer.

Authors:  Carolina Vitale; Antonio Galderisi; Angelantonio Maglio; Paolo Laperuta; Rosa Maria Di Crescenzo; Carmine Selleri; Antonio Molino; Alessandro Vatrella
Journal:  Open Med (Wars)       Date:  2016-11-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.